These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 31732444

  • 1. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y.
    Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ, Dutch Initiative on Crohn and Colitis (ICC).
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
    Yoon H, Ye BD, Kang SB, Lee KM, Choi CH, Jo JY, Woo J, Cheon JH.
    BMC Gastroenterol; 2024 Aug 19; 24(1):273. PubMed ID: 39160459
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.
    Taxonera C, Olivares D, Alba C.
    Inflamm Bowel Dis; 2022 Jan 05; 28(1):32-40. PubMed ID: 33586766
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M, Initiative on Crohn and Colitis.
    Clin Gastroenterol Hepatol; 2023 Jan 05; 21(1):182-191.e2. PubMed ID: 35644343
    [Abstract] [Full Text] [Related]

  • 14. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Uzzan M, Bresteau C, Laharie D, Stefanescu C, Bellanger C, Carbonnel F, Serrero M, Viennot S, Nachury M, Amiot A, Altwegg R, Picon L, Nahon S, Vuitton L, Ah Soune P, Kirchgesner J, Peyrin-Biroulet L, Bouhnik Y, GETAID-TALC Study Group.
    Aliment Pharmacol Ther; 2021 Aug 05; 54(3):312-319. PubMed ID: 34151448
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.
    Steenholdt C, Dige Ovesen P, Brynskov J, Seidelin JB.
    J Crohns Colitis; 2023 Aug 21; 17(8):1354-1363. PubMed ID: 36860164
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panés J.
    Inflamm Bowel Dis; 2021 May 17; 27(6):816-825. PubMed ID: 32766762
    [Abstract] [Full Text] [Related]

  • 20. Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study.
    Dragoni G, Innocenti T, Amiot A, Castiglione F, Melotti L, Festa S, Savarino EV, Truyens M, Argyriou K, Noviello D, Molnar T, Bouillon V, Bezzio C, Eder P, Fernandes S, Kagramanova A, Armuzzi A, Oliveira R, Viola A, Ribaldone DG, Drygiannakis I, Viganò C, Calella F, Gravina AG, Pugliese D, Chaparro M, Ellul P, Vieujean S, Milla M, Caprioli F, “TOFA-poSTOP” Study Group.
    Am J Gastroenterol; 2024 Aug 01; 119(8):1525-1535. PubMed ID: 38305302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.